European Journal of Haematology

Article	Citations
COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome	106
The hematologic consequences of obesity	89
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis	64
The incidence, complications, and treatment of iron deficiency in pregnancy	45
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia	40
The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies	39
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus	38
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series	36
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice	31
Current understanding and future implications of sepsis‐induced thrombocytopenia	27
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy re	27
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies	27
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers	26
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab	26
Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent	25
Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors	24
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019	23
Long‐term follow‐up of patients with venous thromboembolism and COVID‐19: Analysis of risk factors for death and major bleeding	23
Iron chelation therapy	22
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA	22
Comorbidities and complications in adults with pyruvate kinase deficiency	21
Comorbidities in multiple myeloma and implications on survival: A population‐based study	21
Validation of the HScore and the HLH‐2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort	20
The role of oral iron in the treatment of adults with iron deficiency	20
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)	19

Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia	19
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression	18
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world	17
Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies	17
Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment	17
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement	17
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and qual	16
T cell–mediated autoimmunity in immune thrombocytopenia	16
Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review	15
Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation	15
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS	15
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?	14
Acquired aplastic anemia following SARS‐CoV‐2 vaccination	14
Treatment horizon in multiple myeloma	14
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy	14
Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells	14
Real‐world data on voxelotor to treat patients with sickle cell disease	14
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group	13
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement	13
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?	13
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant	13
White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospecti	13
Recombinant factor VIII Fc for the treatment of haemophilia A	13
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study	13
Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML	12
Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review	12
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy	12
A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic f	12
Haploidentical transplantation in pediatric non‐malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)	11
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	11
Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes	11
Molecular pharmacology in complement‐mediated hemolytic disorders	11
Principles of care for acquired hemophilia	11
Image‐guided core needle biopsy as the first‐line diagnostic approach in lymphoproliferative disorders—A review of the current literature	11
Lymphoid malignancy in common variable immunodeficiency in a single‐center cohort	11
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation	11
Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma	11
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution	11
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL	11
Late occurrence of progressive multifocal leukoencephalopathy after anti‐CD19 chimeric antigen receptor T‐cell therapy	10
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis	10
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	10
The hemostatic and thrombotic complications of liver disease	10
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study	10
CAR‐T cell therapy for patients with hematological malignancies. A systematic review	10
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre	10
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis	10
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma	9
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia	9
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?	9

Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	9
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders	9
Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies	9
Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts	9
Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T‐cell therapy	9
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders	9
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia	9
Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study	8
Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐depe	8
Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination	8
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance	8
Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children	8
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics	8
Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms	8
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	8
mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis	8
Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary	7
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis	7
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome	7
Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation	7
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey	7
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)	7
Bleeding complications in bcr‐abl‐negative myeloproliferative neoplasms (MPN): A retrospective single‐center study of 829 MPN patients	7
Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease	7
Translation, validation, and usability of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (Self‐ISTH‐BAT)	7
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma	7
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)	7
Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow‐up	7
“Ex‐vivo” T‐cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges	7
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review	7
Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bon	7
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort	7
Systematic review of hematuria and acute renal failure with tranexamic acid	7
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	7
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series	7
Incidence of adult primary immune thrombocytopenia in England—An update	7
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	7
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	7
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era	7
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera	6
Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA	6
A retrospective study of treosulfan versus busulfan‐based conditioning in pediatric patients	6
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma	6
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients	6
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation	6
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol	6
Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome	6
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases	6
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions	6
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma	6
Clinical utility of targeted next‐generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: A national reference laboratory experience	6
IKZF1plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2	6
Chimeric antigen receptor T cells for acute myeloid leukemia	6
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study	6
Artificial intelligence in the prediction of venous thromboembolism: A systematic review and pooled analysis	6
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome	6
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease	6
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML	6
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review	6
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	6
Congenital erythrocytosis	6
Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees	6
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review	6
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	6
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody	6
A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A	6
Standardization for obtaining blood viscosity: A systematic review	6
Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma	6
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada	5
Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data	5
Clinical and microbiological impact of long‐term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia	5
Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation	5
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	5
Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study	5
A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands	5
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma	5
Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions	5
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study	5
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma	5
Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study	5

Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	5
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trial	5
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial	5
Patterns of previous and secondary malignancies in patients with multiple myeloma	5
Assessment of von Willebrand disease and pregnancy outcomes at regional Australian hospitals	5
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute	5
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma	5
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter inte	5
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation	5
Teclistamab‐cqyv in multiple myeloma	5
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation	5
High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia‐negative myeloproliferative neoplasms	5
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival	5
Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)	5
Evaluation of soluble fibrin monomer complex in patients in SARS‐CoV‐2 COVID‐19 infection‐associated coagulopathy	5
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes	5
The evolution of immune dysfunction in multiple myeloma	5
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?	4
Long‐term survivorship care after CAR‐T cell therapy	4
Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs)	4
Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility	4
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	4
Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle	4
Upregulation of microRNA‐597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition	4
The impact of changed treatment patterns in multiple myeloma on health‐care utilisation and costs, myeloma complications, and survival: A population‐based comparison between two time periods in Denmar	4
Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications	4
Assessment of agreement between EXTEM and NATEM thromboelastometry measurement assays in critically ill neonates	4
Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias	4
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	4
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis	4
Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?	4
Impact of secondary‐type mutations in NPM1 mutated AML	4
The potential etiopathogenetic role and diagnostic utility of CD3+CD56+ regulatory T lymphocytes in Myelodysplastic Syndromes	4
Markers of neutrophil chemotaxis for identification of blood stream infections in children with acute lymphoblastic leukemia undergoing induction treatment	4
The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands	4
Extended treatment response to imatinib in Rosai‐Dorfman disease	4
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	4
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia	4
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK	4
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis	4
Vitamin E and acute graft‐versus‐host disease after myeloablative allogeneic hematopoietic cell transplantation	4
Radiation‐free myeloablative conditioning consisting of fludarabine added to full‐dose busulfan and cyclophosphamide in single‐unit cord blood transplantation for adults	4
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine	4
Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma	4
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	4
Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia	4
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	4
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	4
A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia	4
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	4
Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients	4
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	4
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management	4
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience	4
Screening of the protein C pathway abnormality‐related thrombophilia by using thrombomodulin‐mediated tissue factor‐triggered clot waveform analysis	4
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	4
A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia	4
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	4
Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study	4
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors	4
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	4
Prevalence and outcomes of pulmonary embolism with sickle cell disease: Analysis of the Nationwide Inpatient Sample, 2016–2020	4
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study	4
Anakinra versus etoposide‐based therapy added to high‐dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis	4
Characterization and prognostic implication of delayed complete response in AL amyloidosis	4
Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting	4
Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia‐chromosome negative myeloproliferative neoplasms	4
Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non‐Hodgkin lymphoma	4
Clinical, biological, and outcome features of P2RY8‐CRLF2 and CRLF2 over‐expression in pediatric B‐cell precursor acute lymphoblastic leukemia according to the	4
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study	4